Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma

Authors:	Ho-Jin?Shin,Joo?Seop?Chung author-information" > author-information__contact u-icon-before" > mailto:hemon@pusan.ac.kr" title=" hemon@pusan.ac.kr" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,Moo-Kon?Song,Seon-Kyeong?Kim,Sangmin?Choe,Goon-Jae?Cho

Affiliation:	(1) Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, 1-10, Ami-Dong, Seo-Gu, Busan, Korea;(2) Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea;(3) Division of Clinical Pharmacology, Clinical Research Center, Pusan National University Hospital, Busan, Korea;

Abstract:	Purpose The aim of this study was to evaluate the efficacy and toxicity of reduced-dose (RD) RCHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy for elderly patients with diffuse large B-cell lymphoma (DLBCL).

Keywords:
本文献已被 PubMed SpringerLink 等数据库收录！